• Gilead will hold its annual meeting on April 30, 2026, via webcast.
• Shareholders will vote on electing nine director nominees to serve for the next year.
• Items up for approval include ratifying Ernst and Young as independent auditor and an advisory vote on named executive officer compensation.
• Shareholders will also vote on approving an amended and restated 2022 equity incentive plan.
• Three shareholder proposals will be voted on, covering an independent board chair policy, a report on extended patent exclusivities and patient access, and a report on risks of ESG and DEI executive compensation metrics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001308179-26-000106), on March 20, 2026, and is solely responsible for the information contained therein.